Acuta Capital Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Acuta Capital Partners’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40,000	Closed	-$800K	–	33
2018 Q3	$800K	Sell	40,000 -10,000	-20%	-$228K	0.29%	28
2018 Q2	$975K	Hold	50,000	–	–	0.17%	48
2018 Q1	$1.01M	Sell	50,000 -82,500	-62%	-$1.4M	0.16%	45
2017 Q4	$1.76M	Buy	132,500 +82,500	+165%	+$1.24M	0.33%	42
2017 Q3	$923K	Buy	+50,000	New	+$932K	0.17%	54

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's AMAG Position: Q1 2015 in Review

Acuta Capital Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2015, closing a stake of 26,596 shares — an estimated $1.13M sold.

Acuta Capital Partners first reported a position in AMAG in Q4 2014 and held it in 1 quarter. The position peaked at $1.13M in Q4 2014. 197 funds tracked by Wall St. Rank hold AMAG as of Q1 2015.

Acuta Capital Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Acuta Capital Partners sold 26,596 AMAG Pharmaceuticals shares in Q1 2015, an estimated $1.13M.
Acuta Capital Partners first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Acuta Capital Partners's AMAG Pharmaceuticals position peaked at $1.13M in Q4 2014.
197 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.